Sinovac Biotech Ltd (SVA) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SINOVAC Announces New Board Pursuant to Privy Council Judgment and Order

Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that...

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SINOVAC Issues Statement Regarding Privy Council Judgment

Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that...

シノバック、手足口病（HFMD）に対する2価ワクチンの第III相臨床試験を開始

手足口病に対する多価ワクチンの第III相臨床試験は世界で初めての試みとなる （ビジネスワイヤ） -- 中国のバイオ医薬品におけるリーディングプロバイダ...

SINOVAC hat eine klinische Phase-III-Studie zu einem bivalenten Impfstoff gegen Hand-Fuß-Mund-Krankheit (HFMD) initiiert

Die weltweit erste klinische Phase-III-Studie zu einem multivalenten HFMD-Impfstoff Sinovac Biotech Ltd. („SINOVAC“ oder das „Unternehmen“...

SINOVAC a lancé un essai clinique de Phase III sur un vaccin bivalent contre la maladie mains-pieds-bouche (MMPB)

Le premier essai clinique de Phase III au monde sur un vaccin multivalent contre la MMPB Sinovac Biotech Ltd. (« SINOVAC » ou la « Société »...

SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)

The first phase III clinical trial on a multivalent HFMD vaccine in the world Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a...

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SINOVAC Reports Unaudited First Half of 2024 Financial Results

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its...

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2023...

Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]